NEW YORK (GenomeWeb) — Quidel said today after the close of the market that it has received de novo clearance from the US Food and Drug Administration to market its Lyra Direct HSV 1+2/VZV multiplex real-time assay.
NEW YORK (GenomeWeb News) – Quidel announced after the close of the market on Thursday the 510(k) clearance by the US Food and Drug Administration of the company's AmpliVue HSV 1+2 Assay for differentiating and detecting herpes simplex viruses 1 and 2.
Packaging isothermal PCR reagents in blisters and using lateral flow detection, researchers at Boston University hope to develop a low-cost, disposable assay for Bordetella pertussis, the causative agent of whooping cough.
NEW YORK (GenomeWeb News) – Quidel reported after the close of the market on Tuesday that its fourth quarter revenues declined 7 percent year over year on slower influenza and respiratory disease business.
NEW YORK (GenomeWeb News) – Quidel announced that for full-year 2013 it anticipates reporting $175 million in revenues.
That would represent a 12 percent bump up from $155.7 million recorded in 2012 and would beat the average analyst estimate of $174.0 million.